AbCellera Biologics (ABCL) pivots to clinical stage as 2025 revenue hits $75M

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the most promising penny stocks under $5 to buy. On February 24, AbCellera Biologics announced its Q4 and full-year 2025 financial results, marking a major transition into a clinical-stage biotechnology company.
Pharmaceutical Technology on MSN

NorthX Biologics and Demeetra collaborate on GMP manufacturing and CLD

The collaboration integrates Demeetra’s CleanCut CHO platforms and cell line services with NorthX Biologics’ GMP manufacturing expertise.

Cross Biologics announces strategic partnership with Regenerative Research Group to deliver premium biologics nationwide

The partnership combines RRG’s FDA-registered, CLIA-certified laboratory and industry-leading biologic products with

Grove Biopharma Reports Preclinical Study in Nature Communications Demonstrating a Novel Approach to MYC and KRAS Degradation

Study represents a significant advancement in Grove’s Bionic Biologics™ platform – CHICAGO--(BUSINESS WIRE)--February 24, 2026-- Grove Biopharma,

Arvix Biologics Expands BioMatrix™ Modular Platform for Surgical and Wound-Care Use

The Arvix BioMatrix™ platform is a modular biologic system comprising Base™, Core™, and Prime™ components designed to
WebMD

Is It Time to Try a Biologic for CSU?

If you have chronic spontaneous urticaria (CSU) and treatments like antihistamines and steroids aren’t helping, medicines called biologics might be a good choice for you. Biologics are medicines that target specific antibodies, molecules, and cell ...
Dermatology Advisor

Biologics for Psoriasis Are Safe in Patients With Recent or Active Cancer

Biologic therapies are safe for use in patients with psoriasis who also have active or recent cancer when compared with conventional therapies.